⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3979258 | 0.68 | — | — | |
| SCHEMBL8565027 | 0.67 | — | — | |
| SCHEMBL8792360 | 0.61 | LMNA (0.37) | — | |
| SCHEMBL1755914 | 0.54 | — | — | |
| SCHEMBL5800702 | 0.49 | — | — | |
| SCHEMBL12154070 | 0.46 | — | — | |
| SCHEMBL4786313 | 0.46 | — | — | |
| SCHEMBL16114785 | 0.41 | — | — | |
| SCHEMBL2554291 | 0.41 | — | — | |
| SCHEMBL3884483 | 0.41 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016001266-A1 | FLUORO-[1,3]OXAZINES AS BACE1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-01-07 | — | — | WO | claimed |
| EP-3555080-B1 | OXAZINE DERIVATIVES AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC (US) | 2023-09-20 | — | — | EP | disclosed |
| EP-3655406-A1 | SUBSTITUTED PYRROLOPYRIDINE-DERIVATIVES | Bayer Pharma Aktiengesellschaft (DE) | 2020-05-27 | — | — | EP | disclosed |
| WO-2019016071-A1 | SUBSTITUTED PYRROLOPYRIDINE-DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-01-24 | — | — | WO | disclosed |
| US-9611261-B2 | Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use | AMGEN INC. (US) | 2017-04-04 | — | — | US | disclosed |
| EP-2984086-A1 | BACE1 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2016-02-17 | — | — | EP | disclosed |
| EP-2964644-A1 | PERFLUORINATED CYCLOPROPYL FUSED 1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | Amgen Inc. (US) | 2016-01-13 | — | — | EP | disclosed |
| WO-2016001266-A1 | FLUORO-[1,3]OXAZINES AS BACE1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-01-07 | — | — | WO | disclosed |
| EP-2961749-A1 | PERFLUORINATED 5,6-DIHYDRO-4H-1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | Amgen Inc. (US) | 2016-01-06 | — | — | EP | disclosed |
| CN-105164121-A | Perfluorinated cyclopropyl-fused 1, 3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use thereof | AMGEN INC | 2015-12-16 | — | — | CN | disclosed |
| EP-2948446-A1 | FLUORO-[1,3]OXAZINES AS BACE1 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2015-12-02 | — | — | EP | disclosed |
| WO-2015132141-A1 | 1,3-OXAZINE-2-AMINE DERIVATIVES ACTING AS BACE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2015-09-11 | — | — | WO | disclosed |
| US-9085576-B2 | Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use | AMGEN INC. (US) | 2015-07-21 | — | — | US | disclosed |
| WO-2014166906-A1 | BACE1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-10-16 | — | — | WO | disclosed |
| WO-2014138484-A1 | PERFLUORINATED CYCLOPROPYL FUSED 1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2014-09-12 | — | — | WO | disclosed |
| WO-2014134341-A1 | PERFLUORINATED 5,6-DIHYDRO-4H-1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC. (US) | 2014-09-04 | — | — | WO | disclosed |
| WO-2014114532-A1 | FLUORO-[1,3]OXAZINES AS BACE1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-07-31 | — | — | WO | disclosed |
| WO-2011101304-A2 | PIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-25 | — | — | WO | disclosed |